 buy cabometyx miss season
messag report financi result cabometyx sale miss
street consensu season similar compani includ
increas donut hole exposur higher medicaid payer mix inventori movement
slightli lower volum growth management remain bullish continu growth volum
kidney cancer rcc earli launch liver cancer indic
demand seem acceler exit pipelin updat focus initi new
phase trial front-lin rcc updat estim reflect
season headwind higher public health servic ph util result
slight cabometyx revenu miss report total revenu
street consensu miss slightli cabometyx sale
vs consensu sequenti qoq cabometyx growth driven
volum price growth off-set gross-to-net price adjust
inventori decreas inventori stand
low end histor rang view could potenti rebound increas
gross-net adjust driven increas public payer mix part coverag
gap forecast see preview assum volum growth chang
g/n inventori
management bullish exit strong underli fundament good posit
rcc cabometyx share within tki market continu grow
tki declin account market basket nrx vs nrx
prior share rcc continu increas patient progress
checkpoint inhibitor combin share stabl management point
demand growth increas toward end first quarter
posit earli sign cabometyx label expans new indic contribut
half overal demand growth new patient start contribut
overal net sale accord management translat
quarter caveat appar launch trajectori may alter off-label use
prior manag seem bullish regard earli metric launch
exceed intern expect note share gain stivarga bayri increas
account access sale forc prescrib previous use cabometyx
rcc note uptak academ commun center
cabometyx commerci potenti continu broaden trial
front-lin rcc initi exel-sponsor phase trial
evalu cabometyx opdivo yervoy random opdivo yervoy front-
line intermediate- poor-risk rcc patient trial addit
data readout schedul evalu cabometyx opdivo sutent
rcc phase trial evalu cabometyx
differenti thyroid cancer dtc well line liver cancer respect
cotel licens back anoth shot goal two potenti snda
file year fulli enrol phase pivot trial previous untreat melanoma
set read year posit partner guid snda file
trilog evalu cotel zelboraf tecentriq braf mutation-
posit local advanc metastat diseas evalu cotel
tecentriq braf wild-typ metastat diseas account opportun
cotel model estim
page analyst certif import disclosur
updat estim reflect financi result maintain buy rate
end bn cash invest slightli decreas
cabometyx sale forecast reflect financi result
page analyst certif import disclosur
valuat risk
valu inc per share use dcf base valuat method
valuat includ commerci product cabometyx cometriq well probability-adjust cash
flow deriv compani pipelin royalti out-licens program use
discount rate termin growth rate appli termin year post-assum
gener entri cabozantinib
risk valuat inc includ regulatori commerci setback potenti
emerg new competitor lower product sale expect
page analyst certif import disclosur
licens contract revenu
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
